To protect our staff and visitors from COVID-19, OPA office staff will work remotely. We’ll continue to be fully operational to serve our members. 

Please contact us at: 416-441-0788, toll-free: 1-877-341-0788 or mail@opatoday.com.

Publications

  • News for the Week of August 4, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • Preparing for Stage 3 and Flu Season
    • Encourage Your Patients to Download the COVID Alert App to Prevent Community Spread of COVID-19
    • COVID-19 Resources and Tools
    • External Research Initiatives and Resources

    • Ask the Practice Support Network

    • Complimentary Live Webinar: Landmark Changes in Asthma Management

    • Surviving a Critical Illness
    • Professional Liability Insurance Claims Reporting

    • Health Canada Drug Shortages Updates, July 29, 2020

    • DDD Notice No. 20128 posted August 4, 2020 Prescription Forgery Alert
    • DDD Notice No. 20127 posted August 4, 2020 Prescription Forgery Alert
    • DDD Notice No. 20124 posted July 30, 2020 Executive Officer Notice: Inspections Return to Work

    • Health Product InfoWatch, July 2020
    • Recall of Certain Hand Sanitizers That May Pose Health Risks
    • Non-Prescription Pain Relief Products Containing Codeine Are Not Recommended for Use in People Under 18 Years of Age

  • News for the Week of July 28, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • OPA Submission - Regulatory Amendments to Ontario Regulation 202/94 (General) made under the Pharmacy Act, 1991
    • OPA Submission – Proposed Regulatory Amendments to Ontario Regulation 329/04 under the Personal Health Information Protection Act, 2004
    • Pharmacy Audits by Third-party Payors on ODB Co-payments Submitted During the Ministry's COVID-19 Supply Limit Recommendation
    • Reminder: Express Scripts Canada (ESC) Claims Submissions over $9,999.99

    • Ask the Customer Experience and Administration Team

    • The MASTER Plan for Diabetes Continuing Education Program
    • Mastering Injections in Pediatrics
    • Providing LGBTQ+ Inclusive Care at Your Pharmacy

    • Hospital Coverage Is Provided by Your OPA Secure Health Plan
    • Pharmacy Risk Prevention Tips

    • DDD Notice No. 20123 Posted July 28, 2020 Prescription Forgery Alert
    • DDD Notice No. 20121 Posted July 24, 2020: Notice from the Executive Officer – Monitored Drugs List (MDL) Update Effective: July 24, 2020
    • DDD Notice No. 20120 Posted July 24, 2020: ODB Formulary Edition No. 43, Summary of Changes – July 31, 2020
    • DDD Notice No. 20119 Posted July 24, 2020 Prescription Forgery Alert

    • Status of Ranitidine Drugs in Canada
    • Remdesivir Authorized with Conditions for the Treatment of Patients in Canada with Severe COVID-19 Symptoms

  • News for the Week of July 21, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • Reminder: Public Consultation on the Regulatory Amendments for Expansion of Scope Closing July 27, 2020
    • Non-Insured Health Benefits (NIHB) Program Providers Update
    • Concerns, Beliefs and Attitudes of Pharmacists About Cannabis Use Survey
    • New Episode of Pharmacists' Matters Available Now

    • Ask the Practice Support Network
    • Reduced Pricing on Hand Sanitizer for Pharmacy Professionals

    • An Update on Direct Oral Anticoagulation
    • Managing Your Pharmacy: The Business Essentials
    • Board Certified Geriatric Pharmacist (BCGP) Preparation Course – Medication Therapy Management for Older Adults

    • Why Students Need Life Insurance
    • Dependent Children’s Insurance

    • Importation of PTU™ (Propylthiouracil) 50 mg due to Shortage of Canadian Labelled Propylthiouracil 50 mg Products

    • DDD Notice No. 20117 Posted July 21, 2020 Prescription Forgery Alert
    • DDD Notice No. 20116 Posted July 15, 2020 Prescription Forgery Alert

    • Three Lots of Antidiuretic DDAVP Spray Recalled Because of Potential Overdose Risk
    • Health Canada Important Safety Information on Methadone Treatment of Opioid Dependence and Potential Risk of Lack of Effect when Switching between Different Products

  • News for the Week of July 14, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • ODPRN Ontario Prescription Opioid Tool: Quarterly Update – COVID-19 Insights
    • Update from the Canadian Red Cross
    • TELUS Health 2020 Health Drug Data Trends and National Benchmarks Report
    • CPhA COVID-19 Resource: In-pharmacy Poster for Encouraging Use of Masks

    • Ask the Customer Experience and Administration Team

    • How to Add Value to the Pharmacy Business as a Pharmacy Technician
    • Applying NAPRA's Non-Sterile Compounding Standards Into Practice
    • Mastering Injections in Pediatrics

    • COSECO Insurance Company unites with Co-operators General Insurance Company
    • Do I Need Life insurance?

    • DDD Notice No. 20113 posted July 13, 2020 Prescription Forgery Alert
    • DDD Notice No. 20112 posted July 9, 2020 Prescription Forgery Alert

  • News for the Week of July 7, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • ICYMI: OPA Board Elections
    • FINAL REMINDER: UIIP Application Deadline is Friday, July 10
    • Updated: OPA’s COVID-19 Insurance Exceptions Tool
    • NIHB Program Launches New Claims Processing System and Services via Express Scripts Canada

    • Ask the Practice Support Network
    • Summer Benefit Reminders for OPA Members

    • Pandemic Tips: Return to Work Guidance
    • How Can Pharmacists Optimize the Care of Patients with Heart Failure?
    • The Right Dose: The Positives and Negatives of COVID-19 Testing in Pharmacies

    • Get Your 15% Reduced Driving Refund
    • Are You Insured Through Your Employer’s Group Plan for Long-Term Disability (LTD)?

    • Use of the Drug Picato May Increase the Risk of Skin Cancer
    • Recall of Certain Hand Sanitizers That May Pose Health Risks
    • Certain Vials of Fertility Drug Cetrotide Recalled Because of Potential Contamination
    • Counterfeit Respirators

  • News for the Week of June 30, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • ICYMI: Regulations Posted for Consultation to Allow Pharmacists to Perform Point-Of-Care Tests
    • Updated: COVID-19 Resources and Tools
    • Hand Sanitizers Available to Pharmacies for Resale to Public
    • UIIP Deadline of July 10 is Fast Approaching
    • Express Scripts Canada – Transition to New Claims Processing System
    • ICYMI: New Podcast Released - LGBTQ+ Care in Pharmacy

    • Ask the Customer Experience and Administration Team
    • OPA Conference 2020 Survey Draw Winners

    • Pandemic Tips: Opioid Agonist Therapy

    • OPA Professional Liability — Extended Reporting Period
    • OPA Store Insurance Renewal 2020 - 2021

    • DDD Notice No. 20109 Posted June 29, 2020 Prescription Forgery Alert
    • DDD Notice No. 20108 Posted June 26, 2020 Health Network System (HNS) and Narcotics Monitoring System (NMS) Outage Notification to Ontario Drug Programs Agencies
    • DDD Notice No. 20107 posted June 24, 2020 Introducing SADIE 2.0 – Now With Designates!

    • Recall of Certain Hand Sanitizers That May Pose Health Risks
    • Health Product InfoWatch – June 2020
    • Recall of Certain Hand Sanitizers That Contain Technical-Grade Ethanol
    • NARDIL (Phenelzine Sulfate) Shortage

  • News for the Week of June 23, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • ICYMI: Call for OPA Committee Members
    • New Podcast Episode Released: LGBTQ+ Care in Pharmacy
    • Updated: COVID-19 Resources and Tools
    • Patented Medicine Prices Review Board (PMPRB) Draft Guidelines Consultation
    • OPA's First Virtual Annual General Meeting and Open Forum

    • Ask the Practice Support Network
    • Reminder: Nominate a Candidate for the Bowl of Hygeia

    • Complimentary Live Webcast on June 24: The Positives and Negatives of COVID-19 Testing in Pharmacies
    • Online Program Registration Now Open: Providing LGBTQ+ Inclusive Care At Your Pharmacy
    • Pandemic Tips: Pharmacy Technician’s Role in Supporting Patients and Pharmacy During the Pandemic

    • Business Expense Disability Insurance

    • DDD Notice No. 20104 posted June 22, 2020 Prescription Forgery Alert
    • DDD Notice No. 20105 posted June 22, 2020: ODB Formulary Edition No. 43, Summary of Changes June 30, 2020
    • DDD Notice No. 20106 posted June 23, 2020 Prescription Forgery Alert

    • Health Canada Drug Shortages Updates, June 17, 2020
    • Health Canada Drug Shortages Updates, June 18, 2020

    • Recall of Certain Hand Sanitizers That May Pose Health Risks
    • Important Safety Information on MabCampath (alemtuzumab) – Risk of Haemophagocytic Lymphohistiocytosis, Stroke (including ischaemic and haemorrhagic stroke), and Glomerulonephritis - Sanofi-Aventis Canada Inc.

  • News for the Week of June 16, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • ICYMI: Regulatory Amendments for Expansion of Scope Posted for Public Consultation
    • ICYMI: Removal of the Ministry’s 30-days’ Supply Dispensing Limit Recommendation
    • ICYMI: Message From OPA's CEO: Our Commitment to Create a Diversity Task Force
    • Updated: COVID-19 Resources and Tools
    • Extension of Red Cross First-Aid Certification

    • All OPA Awards Except Bowl of Hygeia Moved to 2021
    • Ask the Customer Experience and Administration Team

    • Pandemic Tips: Leveraging Mobile Apps in Pharmacy During COVID-19

    • Is Protecting Your Family and Business a Priority?
    • ICYMI: Get Your Reduced Driving Refund

    • DDD Notice No. 20102 posted June 12, 2020 Executive Officer Notice: Removal of the 30-days' Supply Dispensing Limit Recommendation

    • Health Canada Drug Shortages Updates, June 15, 2020
    • Health Canada Drug Shortages Updates, June 16, 2020

    • Certain Metformin Diabetes Drugs Recalled Due to the Presence or Possible Presence of NDMA
    • Risk of Poisoning From Hand Sanitizers Sold in Beverage Containers

  • News for the Week of June 9, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • Pharmacist’s Role in Managing Opioid Use Disorder During COVID-19
    • External Research Initiatives and Resources

    • Ask the Practice Support Network
    • OPA’s Newest Member Benefit Partner, Relief Buddy
    • Complete OPA's Conference Survey for a Chance to Win a Prize

    • Pandemic Tips: Leveraging Mobile Apps in Pharmacy During COVID-19

    • Professional Liability Insurance Claims Reporting

    • DDD Notice No. 20100 Posted June 4, 2020 Prescription Forgery Alert

    • Recall of Certain Hand Sanitizers That May Pose Health Risks

Back to top